Share Prices & Company Research

Market News

10 Apr 2019 | 09:18

Alliance Pharma's treatment for nausea and vomiting in pregnancy gains marketing approval in Ireland

Alliance Pharma said its drug to treat nausea and vomiting in pregnancy had gained marketing approval in the Republic of Ireland.

Approval in Ireland would pave the way for the launch of the company's Xonvea treatment in Ireland in the fourth quarter of 2019. The treatment would be marketed directly by Alliance's in-country sales and marketing team, Alliance said.

In Ireland, as in the UK, nausea and vomiting of pregnancy is the most common medical condition in pregnancy, affecting approximately 46,500 women in Ireland each year. At 9:18am: (LON:APH) Alliance Pharma PLC share price was +1.35p at 78.35p

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.